Brexpiprazole
(Redirected from Rexulti)
Atypical antipsychotic medication
| Brexpiprazole | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | Oral |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 913611-97-9 |
| PubChem | 11978813 |
| DrugBank | DB09128 |
| ChemSpider | 10106341 |
| KEGG | D10300 |
Brexpiprazole is an atypical antipsychotic medication used primarily in the treatment of schizophrenia and as an adjunctive therapy for major depressive disorder. It is marketed under the brand name Rexulti.
Medical uses
Brexpiprazole is indicated for the treatment of schizophrenia and as an adjunctive treatment for major depressive disorder (MDD). It is also being studied for the treatment of agitation associated with dementia of the Alzheimer's type.
Mechanism of action
Brexpiprazole acts as a serotonin-dopamine activity modulator (SDAM). It is a partial agonist at 5-HT1A and D2 receptors and an antagonist at 5-HT2A receptors. This unique mechanism of action is thought to contribute to its efficacy in treating both psychotic and mood disorders.
Side effects
Common side effects of brexpiprazole include weight gain, akathisia, and headache. Less common but more serious side effects can include tardive dyskinesia, neuroleptic malignant syndrome, and hyperglycemia.
Pharmacokinetics
Brexpiprazole is administered orally. It has a half-life of approximately 91 hours, allowing for once-daily dosing. The drug is metabolized primarily by the cytochrome P450 enzymes CYP3A4 and CYP2D6.
History
Brexpiprazole was developed by Otsuka Pharmaceutical and Lundbeck. It was approved by the U.S. Food and Drug Administration (FDA) in July 2015 for the treatment of schizophrenia and as an adjunctive treatment for major depressive disorder.
See also
- Atypical antipsychotic
- Schizophrenia
- Major depressive disorder
- Serotonin-dopamine activity modulator
References
External links
Brexpiprazole
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD